Ovarian Cancer Cancer Malignant neoplasm of ovary
Conditions
Interventions
1. Group A: Cisplatin 50 mg/m2 plus 750 mg/m2 cyclophosphamide repeated every 3 weeks for a maximum of six cycles
2. Group B: Cisplatin 100 mg/m2 plus 750 mg/m2 cyclophosphamide repeated every 3 week
Sponsors
Cancer Research UK (CRUK) (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Confirmed diagnosis of invasive epithelial ovarian carcinoma including the following histological subtypes: Serous cystadenocarcinoma; Mucinous cystadenocarcinoma; Endometriod carcinoma; Clear cell (mesonephroid) carcinoma; Undifferentiated carcinoma 2. International Federation of Gynecology and Obstetrics (FIGO) stage Ic, II, III and IV 3. Age 18 -70 years 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 5. Life expectancy of at least 3 months 6. Adequate bone marrow and renal function 7. No previous chemotherapy or radiotherapy 8. No history of previous malignancy, except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix 9. No serious intercurrent disease
Exclusion criteria
Exclusion criteria: Does not match inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed